Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline

Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India

Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

FDA approves Lecanemab autoinjector, marking first at-home treatment for Alzheimer disease

The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease